Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

2.

Advancements in the delivery of epigenetic drugs.

Cramer SA, Adjei IM, Labhasetwar V.

Expert Opin Drug Deliv. 2015;12(9):1501-12. doi: 10.1517/17425247.2015.1021678. Epub 2015 Mar 5. Review.

PMID:
25739728
3.

Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.

Saraf S, Araki H, Petro B, Park Y, Taioli S, Yoshinaga KG, Koca E, Rondelli D, Mahmud N.

Transfusion. 2015 Apr;55(4):864-74. doi: 10.1111/trf.12904. Epub 2014 Nov 2.

4.

St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death.

Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM.

PLoS One. 2014 Jul 30;9(7):e103762. doi: 10.1371/journal.pone.0103762. eCollection 2014.

5.

Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.

Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, Covey JM.

Int J Toxicol. 2014 Mar-Apr;33(2):75-85. doi: 10.1177/1091581814524994. Epub 2014 Mar 17.

6.

NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition.

Osborne JK, Larsen JE, Gonzales JX, Shames DS, Sato M, Wistuba II, Girard L, Minna JD, Cobb MH.

Oncogenesis. 2013 Aug 19;2:e63. doi: 10.1038/oncsis.2013.24.

7.

Adjusting for background mutation frequency biases improves the identification of cancer driver genes.

Evans P, Avey S, Kong Y, Krauthammer M.

IEEE Trans Nanobioscience. 2013 Sep;12(3):150-7. doi: 10.1109/TNB.2013.2263391. Epub 2013 May 16.

8.

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Lim SP, Kumar R, Akkamsetty Y, Wang W, Ho K, Neilsen PM, Walther DJ, Suetani RJ, Prestidge C, Callen DF.

BMC Cancer. 2013 Mar 13;13:113. doi: 10.1186/1471-2407-13-113.

9.

Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y.

Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3.

10.
11.

Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia.

Lendvai Á, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, Klip HG, Hollema H, Jansen RC, Schuuring E, Wisman GB, van der Zee AG.

Epigenetics. 2012 Nov;7(11):1268-78. doi: 10.4161/epi.22301. Epub 2012 Sep 27.

12.

Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.

Somasundaram R, Villanueva J, Herlyn M.

Adv Pharmacol. 2012;65:335-59. doi: 10.1016/B978-0-12-397927-8.00011-7. Review.

13.

The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.

PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.

14.

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.

Nat Genet. 2012 Sep;44(9):1006-14. doi: 10.1038/ng.2359. Epub 2012 Jul 29.

15.

Challenge and promise: the role of miRNA for pathogenesis and progression of malignant melanoma.

Essa S, Denzer N, Mahlknecht U, Klein R, Collnot EM, Reichrath J.

Clin Epigenetics. 2010 Sep;1(1-2):7-11. doi: 10.1007/s13148-010-0001-7. Epub 2010 May 8.

16.

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.

Hassler MR, Klisaroska A, Kollmann K, Steiner I, Bilban M, Schiefer AI, Sexl V, Egger G.

Biochimie. 2012 Nov;94(11):2297-307. doi: 10.1016/j.biochi.2012.05.029. Epub 2012 Jun 9. Review.

17.

Cell cycle gene networks are associated with melanoma prognosis.

Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG.

PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20.

18.

A semantic web framework to integrate cancer omics data with biological knowledge.

Holford ME, McCusker JP, Cheung KH, Krauthammer M.

BMC Bioinformatics. 2012 Jan 25;13 Suppl 1:S10. doi: 10.1186/1471-2105-13-S1-S10.

19.

p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B.

Semin Oncol. 2012 Feb;39(1):97-108. doi: 10.1053/j.seminoncol.2011.11.011. Review.

20.

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y.

Blood. 2012 Feb 2;119(5):1240-7. doi: 10.1182/blood-2011-08-371690. Epub 2011 Dec 7.

Items per page

Supplemental Content

Write to the Help Desk